Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

OptimizeRx (OPRX) EBIT Margin: 2010-2025

Historic EBIT Margin for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to 7.86%.

  • OptimizeRx's EBIT Margin rose 480400.0% to 7.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.17%, marking a year-over-year increase of 382000.0%. This contributed to the annual value of 14.88% for FY2024, which is 220400.0% up from last year.
  • Latest data reveals that OptimizeRx reported EBIT Margin of 7.86% as of Q3 2025, which was up 480400.0% from 10.92% recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's EBIT Margin registered a high of 11.25% during Q4 2024, and its lowest value of 54.32% during Q1 2023.
  • For the 5-year period, OptimizeRx's EBIT Margin averaged around 15.76%, with its median value being 19.93% (2024).
  • As far as peak fluctuations go, OptimizeRx's EBIT Margin plummeted by -340400bps in 2023, and later skyrocketed by 496800bps in 2024.
  • Quarter analysis of 5 years shows OptimizeRx's EBIT Margin stood at 3.06% in 2021, then plummeted by -244bps to 4.4% in 2022, then plummeted by -774bps to 38.43% in 2023, then soared by 129bps to 11.25% in 2024, then plummeted by -30bps to 7.86% in 2025.
  • Its EBIT Margin was 7.86% in Q3 2025, compared to 10.92% in Q2 2025 and 9.64% in Q1 2025.